Clearmind Medicine Inc. (CMND)
CMNDNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$5.22
-0.2850 (-5.18%) today
Regular session, Nov 10, 3:26 PM ET
- Market cap
- $2.65m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $5.21 to $5.76
- 52-week range
- $5.25 to $2,268.37
- Average volume
- 66.9k
- Previous close
- $5.50
Financials
| Quarter | Jul 2022 | Oct 2022 |
|---|---|---|
| Revenue | – | – |
| Gross profit | – | – |
| Operating income | -$1.43m | -$820.0k |
| Net income | -$1.56m | -$1.22m |
News
8 latest- Clearmind Advances CMND-100 Into Patient Testing For Alcohol Use Disorder; Stock Down RTTNews · Oct 27, 2026
- Clearmind Subsidiary Launches Wireless EV-Charging Platform For Autonomous Fleets RTTNews · Oct 12, 2026
- Clearmind Gains Japan Patent Coverage For 3-MMC And PEA Combination RTTNews · Oct 8, 2026
- Clearmind Seeks Streamlined FDA Review For Neuroplastogen Therapies RTTNews · Oct 7, 2026
- Clearmind Reports U.S. Patent Applications For Drug Combinations In Mental Health RTTNews · Sep 26, 2026
- Biotech Stocks In Focus: Aethlon, Tiziana, Capricor, Firefly & Clearmind RTTNews · Sep 17, 2026
- Clearmind Medicine Briefs FDA On Patient Access At Psychedelic Hearing RTTNews · Sep 17, 2026
- Clearmind Advances CMND-100 With First AUD Patients Enrolled RTTNews · Sep 11, 2026
The company
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The Company's intellectual property portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- clearmindmedicine.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.